Market Overview

Pfizer Presents Phase 2 Data Which Shows Investigational Therapy PD-0332991 Plus Letrozole Improved Progression Free Survival vs Letrozole Alone

Share:
Related PFE
Is The Dollar Really As Strong As Companies Are Suggesting?
Was It Foreseeable For Pfizer To Lower Its 2015 Guidance?
GDP Growth Brakes Sharply, But Consumers Spend Briskly As Wages Rise (Investor's Business Daily)

Pfizer Inc. (NYSE: PFE) today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. For patients treated with the combination of PD-991 plus letrozole, median PFS was 26.1 months, a statistically significant improvement compared to the median PFS in women who received letrozole alone, which was 7.5 months (HR=0.37 [95% CI: 0.21, 0.63]; P <0.001). These data were presented today and featured in a press conference at the 35^th Annual San Antonio Breast Cancer Symposium (Abstract #S1-6).

Breast cancer is the most commonly diagnosed cancer^1 and the leading cause of cancer death among women worldwide.^2 Estrogen receptor positive, HER2- breast cancer represents approximately 60 percent of all cases of breast cancer.^3 Despite currently available treatments, survival rates for advanced or metastatic breast cancer remain low.^4

Posted-In: News

 

Related Articles (PFE)

Around the Web, We're Loving...

Get Benzinga's Newsletters